These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36090940)

  • 1. Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma.
    Nishimura N; Miyake M; Shimizu T; Tachibana A; Tanaka N; Fujimoto K
    IJU Case Rep; 2022 Sep; 5(5):338-341. PubMed ID: 36090940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma.
    Kawahara T; Hasizume A; Uemura K; Yamaguchi K; Ito H; Takeshima T; Hasumi H; Teranishi JI; Ousaka K; Makiyama K; Uemura H
    Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
    Taguchi S; Kawai T; Ambe Y; Kishitani K; Sugimoto K; Miyakawa J; Nakamura Y; Noda M; Kaneko T; Kamei J; Obinata D; Yamaguchi K; Kakutani S; Furuya Y; Sato Y; Uemura Y; Akiyama Y; Yamada Y; Sato Y; Yamada D; Enomoto Y; Nishimatsu H; Fujimura T; Fukuhara H; Nakagawa T; Takahashi S; Kume H
    Int J Urol; 2023 Dec; 30(12):1180-1186. PubMed ID: 37740409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era.
    Kita Y; Ito K; Sano T; Hashimoto K; Mochizuki T; Shiraishi Y; Araki H; Fujiwara M; Kanamaru S; Takahashi T; Hishiki K; Okada T; Ogawa K; Ito M; Kojima T; Nishiyama N; Matsui Y; Nishiyama H; Kitamura H; Kobayashi T
    Int J Urol; 2022 Jul; 29(7):647-655. PubMed ID: 35304776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer.
    Brower B; McCoy A; Ahmad H; Eitman C; Bowman IA; Rembisz J; Milowsky MI
    Front Oncol; 2024; 14():1326715. PubMed ID: 38711854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
    Yu EY; Petrylak DP; O'Donnell PH; Lee JL; van der Heijden MS; Loriot Y; Stein MN; Necchi A; Kojima T; Harrison MR; Hoon Park S; Quinn DI; Heath EI; Rosenberg JE; Steinberg J; Liang SY; Trowbridge J; Campbell M; McGregor B; Balar AV
    Lancet Oncol; 2021 Jun; 22(6):872-882. PubMed ID: 33991512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial experience of enfortumab vedotin in a patient with metastatic urothelial carcinoma on hemodialysis: Two case reports.
    Mori S; Matsuo T; Honda H; Araki K; Mitsunari K; Ohba K; Mochizuki Y; Imamura R
    IJU Case Rep; 2024 Jul; 7(4):324-328. PubMed ID: 38966765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin.
    Shafique MA; Haseeb A; Siddiq MA; Mussarat A; Rangwala HS; Mustafa MS
    Cancer Manag Res; 2023; 15():699-706. PubMed ID: 37485038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durable Response After Combination Therapy With Enfortumab Vedotin and Radiotherapy in Metastatic Urothelial Carcinoma: A Report of Two Cases.
    Ikarashi D; Kikuchi K; Takahashi K; Ariga H; Obara W
    Cureus; 2023 Dec; 15(12):e49936. PubMed ID: 38179399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-course treatment after complete response to pembrolizumab in metastatic urothelial bladder cancer: a case series.
    Plais H; Dumont C; Gauthier H; Culine S
    Immunotherapy; 2023 Jul; 15(10):729-735. PubMed ID: 37139988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report.
    Isoda B; Shiga M; Kandori S; Nagumo Y; Yoshino T; Ikeda A; Kawahara T; Kimura T; Negoro H; Hoshi A; Mathis BJ; Nishiyama H
    Case Rep Oncol; 2023; 16(1):414-418. PubMed ID: 37384209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myasthenia gravis with myositis induced by pembrolizumab therapy in a patient with metastatic urothelial carcinoma.
    Hayakawa N; Kikuchi E; Suzuki S; Oya M
    Int Cancer Conf J; 2020 Jul; 9(3):123-126. PubMed ID: 32582515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A radiological complete response to pembrolizumab in a patient with metastatic upper urinary tract urothelial cancer and Lynch syndrome.
    Oki R; Urasaki T; Ueki A; Inamura K; Komai Y; Takahashi S; Yonese J; Yuasa T
    IJU Case Rep; 2023 Jan; 6(1):33-36. PubMed ID: 36605683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of pagetoid spread of urothelial carcinoma with notable reduction achieved through enfortumab vedotin, resulting in complete surgical resection.
    Tokuoka K; Muramoto K; Sakanaka K; Yoshihara K; Yamamoto S; Imai Y; Iwatani K; Tashiro K; Murakami M; Harada T; Hayashimoto T; Umemori M; Kimura T; Shimomura T; Urabe F
    Int Cancer Conf J; 2024 Oct; 13(4):510-514. PubMed ID: 39398921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enfortumab Vedotin in metastatic bladder cancer: a case report of durable clinical efficacy in a pretreated patient.
    Passalacqua MI; Squeri A; Sciumè C; Ieni A; Santarpia M
    Acta Biomed; 2023 Mar; 94(S1):e2023070. PubMed ID: 36883626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
    Maiorano BA; Catalano M; Maiello E; Roviello G
    Front Oncol; 2023; 13():1254906. PubMed ID: 37781180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New paradigms in the second line treatment for advanced and metastatic urothelial carcinoma.].
    Vidal N; Puente J
    Arch Esp Urol; 2020 Dec; 73(10):1007-1015. PubMed ID: 33269719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney.
    Kamei J; Yokoyama H; Niki T; Suda R; Sugihara T; Fujisaki A; Ando S; Iwami D; Fujimura T
    IJU Case Rep; 2022 May; 5(3):199-202. PubMed ID: 35509786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased expression of ATP-binding cassette transporters in enfortumab vedotin-resistant urothelial cancer.
    Kotono M; Kijima T; Takada-Owada A; Okubo N; Kurashina R; Kokubun H; Uematsu T; Takei K; Ishida K; Kamai T
    IJU Case Rep; 2024 Mar; 7(2):173-176. PubMed ID: 38440718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma.
    Cathomas R; Lorch A; Bruins HM; Compérat EM; Cowan NC; Efstathiou JA; Fietkau R; Gakis G; Hernández V; Espinós EL; Neuzillet Y; Ribal MJ; Rouanne M; Thalmann GN; van der Heijden AG; Veskimäe E; Alfred Witjes J; Milowsky MI;
    Eur Urol; 2022 Jan; 81(1):95-103. PubMed ID: 34742583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.